{"id":98935,"date":"2024-06-27T09:21:44","date_gmt":"2024-06-27T09:21:44","guid":{"rendered":"https:\/\/www.mymsd.ch\/it\/?p=98935"},"modified":"2026-03-02T15:03:49","modified_gmt":"2026-03-02T15:03:49","slug":"nuove-terapie-per-i-tumori-gastrointestinali","status":"publish","type":"post","link":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/","title":{"rendered":"Nuove terapie per il trattamento dei tumori gastrointestinali"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" height=\"313\" width=\"1024\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?w=1024\" alt=\"digestive system banner\" class=\"wp-image-98941\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg 5000w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=300,92 300w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=768,235 768w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=1024,313 1024w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=1536,470 1536w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=2048,626 2048w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=320,98 320w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=120,37 120w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT-1.jpg?resize=1400,428 1400w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--df6c1e5e407d40d80f9bb6b44a62531f mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--fe763c3787e6a4fdf4ee6f27bc26c903 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<h3 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color has-teal-500-color has-text-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--65aa941de96e4a87c7e89afb19670a53\">Swissmedic ha omologato altre tre terapie con KEYTRUDA\u00ae per i tumori gastrointestinali<sup>1<\/sup><\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--e66ca3354f305e5ee3d5e748ef70db68\">Da subito KEYTRUDA\u00ae \u00e8 disposizione sua e dei suoi\/delle sue pazienti come indicato qui sotto:<\/h4>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-columns--align-center mhh-mcn-columns--vertical-alignment-top mhh-mcn-v1-columns--f8d53f1f3517a0efc86bc9055db4afec mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--9ee2104fe1aff8b2a61d58efc4bf2dd9 mhh-mcn-column mhh-mcn-column--7 mhh-mcn-column--m-3 mhh-mcn-column--l-3\">\n    \n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--align-center mhh-mcn-v1-image--c262a519a00d9de717611e3d99163a30\">\n                <a\n        class=\"mhh-mcn-anchor-for-image\"\n        href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/gastric\/\"\n        rel=\"noreferrer noopener\"\n        target=\"_blank\"\n    >\n            <img loading=\"lazy\" decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--thumbnail wp-image-98650\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/05\/Karzinom-des-Magens1.png?w=150&#038;h=150&#038;crop=1&#038;quality=80&#038;lossy=1\"\n        width=\"150\"\n        height=\"150\"\n                alt=\"stomach icon\"\n            \/>\n        <\/a>\n        <\/figure>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--a56f9f649e7b77962c2d9bb778966f10 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-9 mhh-mcn-column--l-9\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--2c254fb32a2874a90f18d80ad9eb7082\"><strong><mark class=\"has-inline-color has-teal-500-color\"><a href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/gastric\/\" target=\"_blank\" rel=\"noreferrer noopener\">NOVIT\u00c0: Carcinoma dello stomaco\/della GEJ<\/a><\/mark><\/strong><\/h4>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--011b780e5f44a9b5f41a09e55cad5e47 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--f37717573ca5fd376c916ff17587fefd mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--cbe6c52ea4d62997401ac896aa3c8634 wp-block-paragraph\"><strong>1L terapia combinata per l&#8217;adenocarcinoma HER2-positivo avanzato dello stomaco\/della GEJ<\/strong> KEYTRUDA\u00ae in combinazione con trastuzumab e chemioterapia a base di fluoropirimidina e platino, \u00e8 indicato nel trattamento di prima linea dell&#8217;adenocarcinoma dello stomaco o della giunzione gastroesofagea (GEJ) HER2-positivo, localmente avanzato, non resecabile o metastatico negli adulti i cui tumori esprimono PD-L1 con un CPS \u22651.<\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--16c976c77165347bc77e0d5c1c17d71d\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--37b09659ecf7cc196b8f7a8b76161c9e\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/gastric\/kn811\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Indicazione Keytruda Carcinoma gastrico (KN811)\">\n                    <span class=\"mhh-mcn-v1-link__label\">Allo studio KEYNOTE-811<sup>2<\/sup><\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--b94b46aadfa2b6bddc4e526b7e131c5c mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--f5d5c11e06db88d0eec1e2677c259b84 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--12aad3b0b62141db533caeb19abf1198 wp-block-paragraph\"><strong>1L <strong><strong>terapia combinata<\/strong><\/strong> per l&#8217;adenocarcinoma HER2-negativo avanzato dello stomaco\/della GEJ<\/strong> KEYTRUDA\u00ae in combinazione con chemioterapia a base di fluoropirimidina e platino, \u00e8 indicato nel trattamento di prima linea dell\u2019adenocarcinoma dello stomaco o della giunzione gastroesofagea HER2-negativo, localmente avanzato, non resecabile o metastatico negli adulti i cui tumori esprimono PD-L1 con un CPS \u22651.<\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--f458f2ed4696256f5def1edba5692daa\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--4a1e5351c04432756f768b5140361a40\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/gastric\/kn859\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Indicazione Keytruda Carcinoma gastrico (KN859)\">\n                    <span class=\"mhh-mcn-v1-link__label\">Allo studio KEYNOTE-859<sup>3<\/sup><\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-columns--align-center mhh-mcn-columns--vertical-alignment-top mhh-mcn-v1-columns--33405eda3776a509bf7b5c173f204893 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--f3c6b2b8e043986a4a80edc789ec1555 mhh-mcn-column mhh-mcn-column--7 mhh-mcn-column--m-3 mhh-mcn-column--l-3\">\n    \n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--align-center mhh-mcn-v1-image--27800d083bb25d5b535a2de165ae21ab\">\n                    <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--thumbnail wp-image-98444\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/05\/Gallengangskarzinom.png?w=150&#038;h=150&#038;crop=1&#038;quality=80&#038;lossy=1\"\n        width=\"150\"\n        height=\"150\"\n        loading=\"lazy\"        alt=\"liver with bile ducts icon\"\n            \/>\n            <\/figure>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--95625b0ecb39c308103b254754467ca7 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-9 mhh-mcn-column--l-9\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--ee7b0b42805e0f087b3667f79f596977\"><strong><mark class=\"has-inline-color has-teal-500-color\">NOVIT\u00c0: Carcinoma biliare<\/mark><\/strong><\/h4>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--6866b08802b64cd7e864deacf1b63eab mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--ab2a4629da9a8421b95f99bf7d6ff2b4 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1b68475155570b6c8cc7081fb726bde2 wp-block-paragraph\"><strong>1L <strong><strong>terapia combinata<\/strong><\/strong><\/strong> KEYTRUDA\u00ae in associazione a gemcitabina e cisplatino \u00e8 indicato nel trattamento di prima linea di pazienti adulti con carcinoma biliare (BTC) localmente avanzato, non resecabile o metastatico.<\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--106ea547b55afce69b575e0b1307027c\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--dace4a80117d261412931a3cf0bf44ab\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/kn966\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Indicazione Keytruda Carcinoma gastrico (KN966)\">\n                    <span class=\"mhh-mcn-v1-link__label\">Allo studio KEYNOTE-966<sup>4<\/sup><span><\/span><\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-columns--align-center mhh-mcn-columns--vertical-alignment-top mhh-mcn-v1-columns--84a7d145ab010f5f2f27fadceaf74e09 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--2e7c1643b6aacaaf5b76bc5e2c1236fe mhh-mcn-column mhh-mcn-column--7 mhh-mcn-column--m-3 mhh-mcn-column--l-3\">\n    \n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--align-center mhh-mcn-v1-image--d49ed9a2e98847ef6e06abb0b003a2f0\">\n                <a\n        class=\"mhh-mcn-anchor-for-image\"\n        href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/colorectal\/\"\n        rel=\"noreferrer noopener\"\n        target=\"_blank\"\n    >\n            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--thumbnail wp-image-98341\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/05\/Kolorektales-Karzinom.png?w=150&#038;h=150&#038;crop=1&#038;quality=80&#038;lossy=1\"\n        width=\"150\"\n        height=\"150\"\n        loading=\"lazy\"        alt=\"large intestine icon\"\n            \/>\n        <\/a>\n        <\/figure>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--afc4d3be2a18d0461d2a7fe167c9280f mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-9 mhh-mcn-column--l-9\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--7698cff1e0451a19e3926ee8220d9985\"><strong><mark class=\"has-inline-color has-teal-500-color\"><a href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/colorectal\/\" target=\"_blank\" rel=\"noreferrer noopener\">Carcinoma del colon-retto con MSI-H\/dMMR<\/a><\/mark><\/strong><\/h4>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--4156efa37e6e7eab8fe1d5f2e21a9fe8 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--c917d80447a4b04112374e455ab5d8f4 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b7b63ebf88aca28e3804967ed7dbdd4c wp-block-paragraph\"><strong>1L monoterapia<\/strong> KEYTRUDA\u00ae in monoterapia \u00e8 indicato nel trattamento di prima linea del carcinoma metastatico del colon-retto (CRC) con elevata instabilit\u00e0 dei microsatelliti (MSI-H) o con deficit del sistema di riparazione (dMMR) del DNA negli adulti.<\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--78b8b4a6c7f530f3b14d40a9420dd311\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--b97293a671ccf14d75b32a2df755cb73\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/colorectal\/kn177\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Indicazione Keytruda Carcinoma colorettale (KN177)\">\n                    <span class=\"mhh-mcn-v1-link__label\">Allo studio  KEYNOTE-177<sup>5<\/sup><\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--076d566adf74079da0a721f9572e8692 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--77ea9770b55d9c0d4cb6bcf2a66192fe mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f5181d39197d40a6a16cd5f1e0abf84d wp-block-paragraph\"><strong>2L monoterapia<\/strong> KEYTRUDA\u00ae in monoterapia \u00e8 indicato nel trattamento di pazienti adulti con carcinoma del colon-retto (CRC) non resecabile o metastatico con elevata instabilit\u00e0 dei microsatelliti (MSI-H) o con deficit del sistema di riparazione (dMMR) del DNA dopo una precedente terapia a base di fluoropirimidina in combinazione con irinotecan o oxaliplatino.<\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--c5f2e3f82f1ff65ddcf680645ed9e149\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--c4c93365b9bfebfc033ab8089bf975be\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/colorectal\/kn164\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Indicazione Keytruda Carcinoma colorettale (KN164)\">\n                    <span class=\"mhh-mcn-v1-link__label\">Allo studio KEYNOTE-164<sup>6<\/sup><\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-columns--align-center mhh-mcn-columns--vertical-alignment-top mhh-mcn-v1-columns--616d71677be7d5f8912be62dd2e7045f mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--fc8773d81e2df5b8a93aacf1c8c6d27e mhh-mcn-column mhh-mcn-column--7 mhh-mcn-column--m-3 mhh-mcn-column--l-3\">\n    \n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--align-center mhh-mcn-v1-image--885314be13d80d4e03fd737e8e329746\">\n                    <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--thumbnail wp-image-98388\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/05\/MSI-H-oder-dMMR.png?w=150&#038;h=150&#038;crop=1&#038;quality=80&#038;lossy=1\"\n        width=\"150\"\n        height=\"150\"\n        loading=\"lazy\"        alt=\"MSI-H o dMMR\"\n            \/>\n            <\/figure>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--2d34898d0b0bd63f3b55033b16183d0b mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-9 mhh-mcn-column--l-9\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--a25e16e3dd4e67dfda7136e1eaefb385\"><strong><mark class=\"has-inline-color has-teal-500-color\">Carcinoma gastrico, dell\u2019intestino tenue e delle vie biliari con MSI-H o dMMR<\/mark><\/strong><\/h4>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--598d2b1464de14a738a48944c506e929 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--ed0f3e1ef7882dea5fe71de066c3a3b0 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b686d775ce41cac52aab205528e9594a wp-block-paragraph\"><strong>2L+ <strong>monoterapia<\/strong><\/strong> KEYTRUDA\u00ae in monoterapia \u00e8 indicato per il trattamento di pazienti adulti con carcinoma metastatico gastrico, dell\u2019intestino tenue o delle vie biliari con elevata instabilit\u00e0 dei microsatelliti (MSI-H) o con deficit del sistema di riparazione (dMMR) del DNA in progressione dopo la terapia standard e per i quali non sono disponibili alternative di trattamento soddisfacenti.<\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--cf2e233fef049ea290a1b65d57fe7023\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--fef4e97a6b455bdc4f9b5c68a182dcd0\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/gastrointestinal-cancers\/kn158\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Indicazione Keytruda Cancro gastrointestinale (KN158)\">\n                    <span class=\"mhh-mcn-v1-link__label\">Allo studio KEYNOTE-158<sup>7<\/sup><\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--37c9aed36d33281b3c1c3e6e7f418e74\">Il portafoglio di KEYTRUDA\u00ae \u00e8 in crescita costante<\/h4>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--287de0824bafd6f5e67f1d7728e2d0b6 wp-block-paragraph\">Alla MSD lavoriamo instancabilmente per fornire terapie che diano ai\/alle pazienti oncologici\/che una migliore qualit\u00e0 di vita e pi\u00f9 tempo. <strong>Da adesso sei opzioni terapeutiche con KEYTRUDA\u00ae per il trattamento dei tumori gastrointestinali sono a disposizione sua e dei suoi\/delle sue pazienti.<\/strong><\/p>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--18c71e15a3f25044d4f230ed8b571240 wp-block-paragraph\">La preghiamo di notare che il rimborso tramite la cassa malati per le nuove indicazioni \u00e8 ancora in sospeso. Il loro inserimento nell&#8217;elenco delle specialit\u00e0 (ES) dell&#8217;Ufficio federale della sanit\u00e0 pubblica (UFSP) \u00e8 per noi una priorit\u00e0.<\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\r\n<div class=\"inpsyde-iframe is-responsive has-transparent-background-color\">\r\n    <iframe loading=\"lazy\" height=\"400\" referrerpolicy=\"no-referrer-when-downgrade\" title=\"Questo contenuto \u00e8 stato rilevante per Lei?\" src=\"https:\/\/go.screver.com\/msd-ch-cx\/newsroom-articles?lang=it&amp;hideHeader=true\" width=\"100%\"><\/iframe>\r\n<\/div>\n\n\n<section class=\"mhh-mcn-v1-section mhh-mcn-v1-section--626d45167e4377b3e3a9789e804888b3 mhh-mcn-section mhh-mcn-v1-section--align-full\">\n    <div class=\"mhh-mcn-container\">\n    \n\n<h3 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color has-text-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--e94657ebad452fee692fbe855d3bd372\" style=\"color:#000000\">Related Content<\/h3>\n\n\n<div class=\"mhh-mcn-v1-content-items mhh-mcn-v1-content-items--810790f7f117f12f14ea212b52374874 wp-block-mconnect-theme-curated-content mhh-mcn-layout--columns mhh-mcn-columns mhh-mcn-v1-columns--b6f100c117ecce60e2e53fbce07866d3 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        <div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--be9831ab40ed29410a0f0780dc56efe4 mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--2e917e0f5a6d277f8f42f9c6a6aacbb1 with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-54034\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/01\/hero_empathy-white_lo_96dpi.jpg?w=1280&#038;quality=80&#038;lossy=1\"\n        width=\"1280\"\n        height=\"720\"\n        loading=\"lazy\"        alt=\"Utilizza gi\u00e0 i moduli di richiesta di rimborso dei costi di KEYTRUDA\u00ae?\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"L&#039;elemento \u00e8 stato taggato come: MSD Services\">\n    MSD Services<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/it\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/moduli-di-richiesta-di-rimborso-dei-costi-di-keytruda\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        Utilizza gi\u00e0  i moduli di richiesta di rimborso dei costi di KEYTRUDA\u00ae?    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Il numero in continuo aumento delle indicazioni per KEYTRUDA\u00ae omologate da Swissmedic rende difficile sapere sempre quali indicazioni sono rimunerate e se si debba tenere conto di ulteriori limitatio dell\u2019elenco delle specialit\u00e0.<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    Leggi di pi\u00f9<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n<div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--c50f104bc1ddc7b185f0a09022291427 mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--356465614215df5773f39d96064df164 with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-56344\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/05\/article_5_march-thumb-1.png?w=635&#038;quality=80&#038;lossy=1\"\n        width=\"635\"\n        height=\"475\"\n        loading=\"lazy\"        alt=\"Barometro delle cure oncologiche in Svizzera: auspicato un maggiore coordinamento\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"L&#039;elemento \u00e8 stato taggato come: Sondaggio d\u2019opinione\">\n    Sondaggio d\u2019opinione<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/it\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news\/barometro-delle-cure-oncologiche-in-svizzera-auspicato-un-maggiore-coordinamento\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        Barometro delle cure oncologiche in Svizzera: auspicato un maggiore coordinamento    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Il rappresentativo sondaggio d\u2019opinione sulla qualit\u00e0 della cura del cancro in Svizzera dell\u2019istituto di ricerca gfs.bern ha rilevato: la diagnosi precoce e la terapia precoce del cancro sono per gli intervistati gli argomenti pi\u00f9 importanti.<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    Leggi di pi\u00f9<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n<div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--349f987c0c887074bdd31ee3737d3afb mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--c9936dfb40314ad5fcb3318c818cfe4d with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-96864\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/02\/MSD2931-KEYTRUDA-Melanom-KN716-Bilder-fuer-mymsd-600x400-IT-V02-150.png?w=1250&#038;quality=80&#038;lossy=1\"\n        width=\"1250\"\n        height=\"833\"\n        loading=\"lazy\"        alt=\"Nuova opzione di trattamento con KEYTRUDA\u00ae per il melanoma \u00a0\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"L&#039;elemento \u00e8 stato taggato come: Melanoma\">\n    Melanoma<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/it\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news\/nuova-opzione-di-trattamento-con-keytruda-per-il-melanoma\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        Nuova opzione di trattamento con KEYTRUDA\u00ae per il melanoma \u00a0    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Swissmedic ha approvato KEYTRUDA\u00ae per il trattamento del melanoma ad alto rischio nello stadio IIB\/IIC.<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    Leggi di pi\u00f9<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n    <\/div>\n\n    <\/div>\n\n    <\/div>\n<\/section>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--9db3c1e2e9089acf313473ffc1ab41c8\"><strong>Abbreviazioni<\/strong><em>:<\/em><\/h5>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4c8e895e13e40b92f81788348f7ecbf6 wp-block-paragraph\"><strong><em>BTC:<\/em><\/strong> Biliary Tract Cancer (carcinoma biliare); <strong>CPS<\/strong>: combined positive Score (punteggio positivo combinato); <strong>GEJ<\/strong>: gastroesophageal junction (giunzione gastroesofagea); <strong>HER2<\/strong>: Human Epidermal Growth Factor Receptor-2 (recettore 2 per il fattore di crescita epiteliale); <strong>NCCN<\/strong>: National Comprehensive Cancer Network; <strong>PD-L1<\/strong>: Programmed Death-Ligand 1 (ligando 1 di morte cellulare programmata).<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--0a3a0e0291dba1036e6a69d5f008e73d\"><strong>Riferimenti bibliografici:<\/strong><\/h5>\n\n\n\n<ol class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--e703463219730eeffe1297cf74336e03 mhh-mcn-list mhh-mcn-v2-clist--ordered mhh-mcn-v2-clist--ordered-decimal\" dir=\"ltr\" lang=\"it-IT\" start=\"1\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Informazione professionale di KEYTRUDA\u00ae, <a href=\"https:\/\/www.swissmedicinfo-pro.ch\/showText.aspx?textType=FI&amp;lang=IT&amp;authNr=66231&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo-pro.ch<\/a>.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Janjigian YY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 2023;402:2197\u2013208.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Rha SY, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853 \u2013 1865.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Diaz LA, Shiu K-K, Kim T-W, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):P659 \u2013 670. With supplement appendix.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability\u2013high\/mismatch repair\u2013deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11\u201319.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;38(1):1\u201314.    <\/li>\n\n<\/ol>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3fff35f4e4104e66731be5d9105e54e8 wp-block-paragraph\">In caso di bisogno, copie degli studi possono essere richieste all\u2019indirizzo <a href=\"mailto:dpoc.switzerland@msd.com\">dpoc.switzerland@msd.com<\/a><em>.<\/em><\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--a92e78568121cacb69df53e5338bb11d\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--ed481f305d99e8bde247830fb852bf59 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.swissmedicinfo-pro.ch\/showText.aspx?textType=FI&#038;lang=IT&#038;authNr=66231&#038;supportMultipleResults=1\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Informazione professionale di KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Informazione professionale di KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Swissmedic ha omologato altre tre terapie con KEYTRUDA\u00ae per i tumori gastrointestinali.<\/p>\n","protected":false},"author":202221,"featured_media":98939,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","hide_featured_image":true,"primary_tag":1126,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[236,311],"tags":[1126],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[501],"ga4_page_businessunit":[507],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[713],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[280,229],"tx-product":[270],"tx-pathology":[1127],"tx-content-type":[227],"tx-active-ingredient":[],"access":[],"user_status":[6],"user_role":[],"class_list":["post-98935","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-onco-news-it","category-oncology","tag-tumori-gastrointestinali"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuove terapie per il trattamento dei tumori gastrointestinali - MyMSD.ch IT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuove terapie per il trattamento dei tumori gastrointestinali - MyMSD.ch IT\" \/>\n<meta property=\"og:description\" content=\"Swissmedic ha omologato altre tre terapie con KEYTRUDA\u00ae per i tumori gastrointestinali.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch IT\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-27T09:21:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T15:03:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2646\" \/>\n\t<meta property=\"og:image:height\" content=\"1979\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MDM\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"MDM\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/\"},\"author\":{\"name\":\"MDM\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/person\\\/5582d9c89a597dff94818e6008b86ab7\"},\"headline\":\"Nuove terapie per il trattamento dei tumori gastrointestinali\",\"datePublished\":\"2024-06-27T09:21:44+00:00\",\"dateModified\":\"2026-03-02T15:03:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2024\\\/06\\\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg\",\"keywords\":[\"Tumori gastrointestinali\"],\"articleSection\":[\"Onco News IT\",\"Oncology\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/\",\"name\":\"Nuove terapie per il trattamento dei tumori gastrointestinali - MyMSD.ch IT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2024\\\/06\\\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg\",\"datePublished\":\"2024-06-27T09:21:44+00:00\",\"dateModified\":\"2026-03-02T15:03:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2024\\\/06\\\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg\",\"contentUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2024\\\/06\\\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg\",\"width\":2646,\"height\":1979,\"caption\":\"Nuove terapie per il trattamento dei tumori gastrointestinali\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/nuove-terapie-per-i-tumori-gastrointestinali\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuove terapie per il trattamento dei tumori gastrointestinali\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/\",\"name\":\"MyMSD.ch IT\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2026\\\/11\\\/MSD-Logo-square.png\",\"contentUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2026\\\/11\\\/MSD-Logo-square.png\",\"width\":500,\"height\":500,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/person\\\/5582d9c89a597dff94818e6008b86ab7\",\"name\":\"MDM\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g\",\"caption\":\"MDM\"},\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/author\\\/mdalmolin1\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuove terapie per il trattamento dei tumori gastrointestinali - MyMSD.ch IT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/","og_locale":"it_IT","og_type":"article","og_title":"Nuove terapie per il trattamento dei tumori gastrointestinali - MyMSD.ch IT","og_description":"Swissmedic ha omologato altre tre terapie con KEYTRUDA\u00ae per i tumori gastrointestinali.","og_url":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/","og_site_name":"MyMSD.ch IT","article_published_time":"2024-06-27T09:21:44+00:00","article_modified_time":"2026-03-02T15:03:49+00:00","og_image":[{"width":2646,"height":1979,"url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg","type":"image\/jpeg"}],"author":"MDM","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"MDM","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/#article","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/"},"author":{"name":"MDM","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/5582d9c89a597dff94818e6008b86ab7"},"headline":"Nuove terapie per il trattamento dei tumori gastrointestinali","datePublished":"2024-06-27T09:21:44+00:00","dateModified":"2026-03-02T15:03:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/"},"wordCount":502,"publisher":{"@id":"https:\/\/www.mymsd.ch\/it\/#organization"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg","keywords":["Tumori gastrointestinali"],"articleSection":["Onco News IT","Oncology"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/","url":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/","name":"Nuove terapie per il trattamento dei tumori gastrointestinali - MyMSD.ch IT","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg","datePublished":"2024-06-27T09:21:44+00:00","dateModified":"2026-03-02T15:03:49+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/#primaryimage","url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg","contentUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/06\/MSD3007-Onco-Newsroom-Teaser_LandingPage_IT.jpg","width":2646,"height":1979,"caption":"Nuove terapie per il trattamento dei tumori gastrointestinali"},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/nuove-terapie-per-i-tumori-gastrointestinali\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/it\/"},{"@type":"ListItem","position":2,"name":"Nuove terapie per il trattamento dei tumori gastrointestinali"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/it\/#website","url":"https:\/\/www.mymsd.ch\/it\/","name":"MyMSD.ch IT","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/it\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2026\/11\/MSD-Logo-square.png","contentUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2026\/11\/MSD-Logo-square.png","width":500,"height":500,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/5582d9c89a597dff94818e6008b86ab7","name":"MDM","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g","caption":"MDM"},"url":"https:\/\/www.mymsd.ch\/it\/author\/mdalmolin1\/"}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/98935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/users\/202221"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/comments?post=98935"}],"version-history":[{"count":32,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/98935\/revisions"}],"predecessor-version":[{"id":105156,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/98935\/revisions\/105156"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/media\/98939"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/media?parent=98935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/categories?post=98935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tags?post=98935"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_audience?post=98935"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_birn_id?post=98935"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_branding?post=98935"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_businessunit?post=98935"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_campaign?post=98935"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=98935"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=98935"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=98935"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_experience?post=98935"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_indication?post=98935"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_material_intent?post=98935"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_product?post=98935"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_region?post=98935"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=98935"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-therapeutic-area?post=98935"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-product?post=98935"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-pathology?post=98935"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-content-type?post=98935"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-active-ingredient?post=98935"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/access?post=98935"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_status?post=98935"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_role?post=98935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}